{"filing":{"accession_number":"0001193125-26-302580","cik":"0001750149","ticker":"IKT","company_name":"Inhibikase Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"d157026d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526302580/d157026d8k.htm"},"events":[{"id":17754,"run_id":15919,"accession_number":"0001193125-26-302580","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Inhibikase announced the sale of 25 million shares of common stock for $50 million gross proceeds through its at-the-market (ATM) facility to RA Capital Management. This is a registered equity issuance under a shelf registration statement (Form S-3) and ATM prospectus supplement. The sale is material to investors as it represents significant dilution and capital raising activity for a clinical-stage pharmaceutical company, and the proceeds are earmarked to fund operations through a key clinical milestone (Phase 3 IMPROVE-PAH topline data readout).","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16344,"accession_number":"0001193125-26-302580","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibikase announced the sale of 25 million shares of common stock for $50 million gross proceeds through its at-the-market (ATM) facility to RA Capital Management. This is a registered equity issuance under a shelf registration statement (Form S-3) and ATM prospectus supplement. The sale is material to investors as it represents significant dilution and capital raising activity for a clinical-stage pharmaceutical company, and the proceeds are earmarked to fund operations through a key clinical milestone (Phase 3 IMPROVE-PAH topline data readout).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T12:12:38.238074+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16344,"accession_number":"0001193125-26-302580","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibikase announced the sale of 25 million shares of common stock for $50 million gross proceeds through its at-the-market (ATM) facility to RA Capital Management. This is a registered equity issuance under a shelf registration statement (Form S-3) and ATM prospectus supplement. The sale is material to investors as it represents significant dilution and capital raising activity for a clinical-stage pharmaceutical company, and the proceeds are earmarked to fund operations through a key clinical milestone (Phase 3 IMPROVE-PAH topline data readout).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T12:12:38.238074+00:00","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-07-14"}]}